A. Bench

发表

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P. Campbell, A. Green, G. Vassiliou, 2005, The Lancet.

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

A. Green, A. Bench, N. Cross, 2013, British journal of haematology.

Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

M. Leversha, A. Green, J. Chang, 2000, Blood.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

P. Campbell, R. Bowman, A. Green, 2008, Blood.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

T. Barbui, S. Schnittger, P. Guglielmelli, 2013, Leukemia.

Thioredoxin, a mediator of growth inhibition, maps to 9q31.

H. Lehrach, G. Zehetner, A. Bench, 1995, Genomics.

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

P. Campbell, A. Green, J. Reilly, 2008, Haematologica.

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.

L. Campbell, A. Green, A. Bench, 2002, Blood.

Myeloproliferative neoplasms

A. Green, A. Bench, A. Godfrey, 2019, Molecular Hematology 4e.

Methods for detecting mutations in the human JAK2 gene.

A. Green, E. Baxter, A. Bench, 2013, Methods in molecular biology.

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

A. Green, W. Erber, A. Bench, 2011, Blood.

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

A. Green, W. Erber, A. Bench, 2010, British journal of haematology.

studies, cytogenetic associations, and role in leukemic transformation in the myeloproliferative disorders: timing, clonality JAK2 Mutation of

P. Campbell, R. Kusec, A. Green, 2010 .

Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.

P. Campbell, A. Green, W. Erber, 2006, Methods in molecular medicine.

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.

H. Heimpel, M. Griesshammer, A. Green, 2003, Blood.

L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting.

A. Green, A. Ferguson-Smith, G. Vassiliou, 2005, Genomics.

Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

A. Green, A. Bench, B. Huntly, 2003, Blood.

chromosome 9 in chronic myeloid leukemia Double jeopardy from a single translocation : deletions of the derivative

A. Green, A. Bench, B. Huntly, 2003 .

Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution

D. Wedge, I. Varela, N. Bolli, 2017, British journal of haematology.

Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms

L. Happerfield, W. Erber, A. Bench, 2009, British journal of haematology.

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera

A. Green, W. Erber, L. Scott, 2007, British journal of haematology.

Myeloproliferative neoplasms

A. Green, A. Bench, A. Godfrey, 2018, Molecular Hematology 4e.

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling

A. Green, H. Quentmeier, A. Bench, 2014, Leukemia.

A certi ﬁ ed plasmid reference material for the standardisation of BCR – ABL1 mRNA quanti ﬁ cation by real-time quantitative PCR

D. Colomer, T. Lion, M. Jansson, 2015 .

A practical strategy for the routine use of BIOMED‐2 PCR assays for detection of B‐ and T‐cell clonality in diagnostic haematopathology

W. Erber, M. Du, A. Bench, 2007, British journal of haematology.

Cytogenetics of Myeloproliferative Disorders

A. Green, A. Bench, B. Huntly, 2004 .

Abnormalities of the long arm of chromosome 20 in myeloid malignancies

T. L. Hood, A. Green, S. Swanton, 1999 .

Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.

P. Campbell, A. Green, E. Baxter, 2006, Haematologica.

Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies.

A. Green, A. Ferguson-Smith, G. Vassiliou, 2004, Proceedings of the National Academy of Sciences of the United States of America.

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

A. Green, T. Barbui, A. Bench, 2000, Hematology. American Society of Hematology. Education Program.

Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes

T. L. Hood, P. Deloukas, D. Bentley, 2000, Oncogene.

Chromosomal abnormalities and molecular markers in myeloproliferative disorders.

A. Bench, H. Pahl, 2005, Seminars in hematology.

Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms

G. Follows, W. Erber, A. Bench, 2007, International journal of laboratory hematology.

Rescue of the lethal scl(-/-) phenotype by the human SCL locus.

B. Göttgens, A. Green, A. Bench, 2002, Blood.

Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.

W. Erber, A. Bench, M. Scott, 2005, Clinical and laboratory haematology.

Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites.

B. Göttgens, A. Green, A. Bench, 1999, Developmental biology.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

P. Campbell, A. Green, J. Marsden, 2005, The Lancet.

a powerful and independent prognostic indicator in chronic myeloid leukemia

L. Campbell, A. Green, J. Szer, 2001 .

phenotype by the human SCL locus - / - Rescue of the lethal scl

B. Göttgens, A. Bench, S. Piltz, 2013 .

Homozygous deletions at 3p12 in breast and lung cancer

J. Bergh, J. Minna, M. Lerman, 1998, Oncogene.

7 Molecular genetics and cytogenetics of myeloproliferative disorders

A. Green, A. Bench, K. Champion, 1998 .

Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?

D. Ferguson, T. Marafioti, D. Mason, 2010, Haematologica.

A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region.

P. Deloukas, D. Bentley, R. Gwilliam, 1998, Genomics.

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

P. Campbell, M. Griesshammer, A. Green, 2006, Blood.

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

Kirsten R. McEwen, P. Campbell, A. Green, 2013, Clinical Epigenetics.

Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies

P. Deloukas, A. Hunt, A. Green, 2004, British journal of haematology.

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype

J. Martinez-Climent, N. Bolli, G. Gundem, 2014, Leukemia.

W. Erber, A. Bench, M. Scott, 2009, Leukemia.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

C. Tyler-Smith, Z. Ning, J. Chi, 2016, Blood.

Contribution of immunoglobulin lambda light chain gene rearrangement analysis in the diagnosis of B‐cell neoplasms

M. Du, A. Bench, M. Scott, 2019, British journal of haematology.

Clonal antigen receptor gene PCR products outside the expected size range

Mahlon D. Johnson, J. Dongen, P. Rothberg, 2012, Journal of Hematopathology.

The role of molecular genetic analysis within the diagnostic haemato‐oncology laboratory

A. Bench, 2012, International journal of laboratory hematology.

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

H Emons, V Kairisto, S Trapmann, 2014, Leukemia.

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib

G. Follows, T. Zenz, A. Bench, 2013, British journal of haematology.

Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH

A. Green, A. Bench, E. Nacheva, 2003, Leukemia.

Analyses of the extent of shared synteny and conserved gene orders between the genome of Fugu rubripes and human 20q.

Thomas Haaf, Anthony R Green, Sarah F. Smith, 2002, Genome research.

Mutation and methylation analysis of the transforming growth factor β receptor II gene in polycythaemia vera

A. Green, A. Bench, B. Huntly, 2001, British journal of haematology.

High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies

G. Follows, A. Bench, E. Boyd, 2011, British journal of haematology.

Molecular genetics and cytogenetics of myeloproliferative disorders.

A. Green, A. Bench, K. Champion, 1998, Bailliere's clinical haematology.

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

A. Green, W. Erber, A. Bench, 2009, British journal of haematology.

Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2011 .

Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture

P. Ellis, A. Bradley, I. Varela, 2013, Leukemia.

TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.

R. Hamoudi, M. Du, A. Bench, 2007, Leukemia research.

chronic myeloid leukemia translocation and provide a powerful and independent prognostic indicator in Deletions of the derivative chromosome 9 occur at the time of the Philadelphia

L. Campbell, A. Green, A. Bench, 2008 .

Analysis of vertebrate SCL loci identifies conserved enhancers

Berthold Göttgens, Sabine Bahn, D. Grafham, 2000, Nature Biotechnology.

Myeloproliferative disorders.

A. Green, A. Bench, N. Cross, 2001, Best practice & research. Clinical haematology.

chromosome 9 in chronic myeloid leukemia Double jeopardy from a single translocation : deletions of the derivative

A. Green, A. Bench, B. Huntly, 2003 .

Hematopoiesis

B. Göttgens, B. Hoffman, A. Bench, 2002, Oncogene.

KLF 2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and 1 identifies a subset with distinct genotype 2 3

J. Climent, N. Bolli, G. Gundem, 2014 .

MYELOID NEOPLASIA Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

C. Tyler-Smith, Z. Ning, J. Chi, 2016 .

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P. Campbell, A. Green, G. Vassiliou, 2005, The Lancet.

JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera.

P. Campbell, A. Green, J. Marsden, 2005 .

studies, cytogenetic associations, and role in leukemic transformation in the myeloproliferative disorders: timing, clonality JAK2 Mutation of

P. Campbell, A. Green, W. Erber, 2010 .